Safyral is an oral contraceptive drug owned by Bayer Hlthcare. The drug was first authorized for market use on 16th December 2010. It contains active ingredients such as Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium. The drug comes in tablet form and can be taken orally.
Safyral has a total of 3 patents, 1 of which has expired. The generics of the drug could possibly be released after the expiration date of the last patent on 17th July, 2030.
Safyral is mainly used for the prevention of pregnancy. In addition, it is also used to raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnancy.
Safyral is covered by three patents. The final patent with the title 'Pharmaceutical composition containing a tetrahyfolic acid' is set to expire on July 17, 2030. This will likely pave the way for the release of Safyral generics. Below are the details of the patent: